Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19
Open Access
- 24 June 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Blood Science
- Vol. 2 (3) , 71-75
Abstract
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China led to a public health emergency of international concern, putting all health organizations on high alert in the beginning of 2020. Corona virus disease 2019 (COVID-19) is highly infectious and has resulted in thousands of deaths which exceeded that of the SARS coronavirus (SARS-CoV) outbreak back in 2002 and 2003 in China. Besides, the number of diagnosed patients, patients who are suspected to have contracted the disease, and deaths are increasing worldwide. Unfortunately, effective drugs and vaccines to combat SARS-CoV-2 are still lacking. Convalescent plasma, a seemingly successful treatment for COVID-19 patients, proved to be of huge value in terms of saving severely ill patients. This review introduces the reported effects, potential mechanisms, and future uncertainties of convalescent plasma therapy in the treatment of COVID-19 patients, in the hopes that it will provide useful information for relevant physicians and researchers.Keywords
This publication has 50 references indexed in Scilit:
- Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infectionRetrovirology, 2011
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011
- IgM in microbial infections: Taken for granted?Immunology Letters, 2009
- The management of coronavirus infections with particular reference to SARSJournal of Antimicrobial Chemotherapy, 2008
- SARS: Systematic Review of Treatment EffectsPLOS Medicine, 2006
- Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospitalJournal of Antimicrobial Chemotherapy, 2005
- Treatment of severe acute respiratory syndromeEuropean Journal of Clinical Microbiology & Infectious Diseases, 2005
- Use of convalescent plasma therapy in SARS patients in Hong KongEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Antibody-Dependent Enhancement of Ebola Virus InfectionJournal of Virology, 2003
- Infectivity-Enhancing Antibodies to Ebola Virus GlycoproteinJournal of Virology, 2001